| Literature DB >> 16413026 |
Kyeong-Min Lee1, Keun-Gyu Park, Yong-Deuk Kim, Hyo-Jung Lee, Hyoung Tae Kim, Won-Hyun Cho, Hye-Soon Kim, Seong-Wook Han, Gou Young Koh, Joong-Yeol Park, Ki-Up Lee, Jung-Guk Kim, In-Kyu Lee.
Abstract
Vascular inflammation induced by the proinflammatory cytokine/NF-kappaB pathway is one of the key mechanisms in the development of neointimal hyperplasia. Accumulating evidence suggests that a recently identified chemokine, fractalkine, is involved in arterial inflammation and atherogenesis. However, no study has examined the expression of neointimal fractalkine and the effects of pharmacological agents on this process. The purposes of this study were to measure neointimal fractalkine expression in the rat carotid artery following balloon injury and to determine if alpha-lipoic acid (ALA) inhibits fractalkine expression and neointimal hyperplasia. Balloon injury of the rat carotid artery induced fractalkine expression in the medial as well as neointimal regions. ALA inhibited this expression and consequently prevented neoinitmal hyperplasia in a balloon-injured rat carotid artery. Additionally, ALA inhibited TNF-alpha-stimulated fractalkine expression in cultured vascular smooth muscle cells (VSMCs), a process which is mediated through the NF-kappaB pathway. In addition to fractalkine, ALA successfully inhibited TNF-alpha-stimulated expression of vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 in cultured VSMCs. These data suggest that the cytokine-fractalkine system is involved in the pathogenesis of restenosis. The present study supports the possibility that ALA, which inhibits the NF-kappaB/fractalkine pathway, may be used to prevent neointimal hyperplasia after angioplasty or stenting.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16413026 DOI: 10.1016/j.atherosclerosis.2005.12.003
Source DB: PubMed Journal: Atherosclerosis ISSN: 0021-9150 Impact factor: 5.162